 |
110 Diseases |  |
158 Trials |
|
158 Trials |  |
1691 News |  |
| «12345678910111213...2728» |
- || Verzenio (abemaciclib) / Eli Lilly
Enrollment closed, Trial completion date, Trial primary completion date: CARABELA: Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients (clinicaltrials.gov) - Jul 12, 2022
P2, N=200, Active, not recruiting, Sponsor: Spanish Breast Cancer Research Group
Recruiting --> Active, not recruiting | Trial completion date: Jun 2033 --> Feb 2033 | Trial primary completion date: Jun 2023 --> Feb 2023
- | goserelin acetate / Generic mfg.
Bugün kan verdim, port yıkattım, zoladex vuruldu. Kevgir gibiyim 😄 Geçmiş olsun hepimize. (Twitter) - Jun 30, 2022
- || goserelin acetate / Generic mfg.
Evet zoladex. Neden o iğne o kadar kalın anlamıyorum hiç. Sıvı değil partikül transfer ediliyor sanki. @AstraZeneca (Twitter) - Jun 30, 2022
- | FCN-437 / Fosun Pharma
New P3 trial, Combination therapy, Metastases: This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant (clinicaltrials.gov) - Jun 30, 2022
P3, N=312, Recruiting, Sponsor: Ahon Pharmaceutical Co., Ltd.
- | FCN-437 / Fosun Pharma
New P3 trial, Combination therapy, Metastases: This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole (clinicaltrials.gov) - Jun 30, 2022
P3, N=434, Recruiting, Sponsor: Ahon Pharmaceutical Co., Ltd.
- | goserelin acetate / Generic mfg.
Ayrıca muadil zoladex önerildi, doğru tahmin o da piyasada yok😔@saglikbakanligi kadere terk edildik resmen (Twitter) - Jun 29, 2022
- | Viadur (leuprorelin implant) / J&J, Bayer, Eligard (leuprolide acetate) / Tolmar, Sanofi, Recordati
Trial completion: Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer (clinicaltrials.gov) - Jun 15, 2022
P3, N=1579, Completed, Sponsor: Radiation Therapy Oncology Group
Recruiting --> Active, not recruiting | Trial completion date: Jun 2033 --> Feb 2033 | Trial primary completion date: Jun 2023 --> Feb 2023 Unknown status --> Completed
- || goserelin acetate / Generic mfg., anastrozole / Generic mfg.
سلامات إن شاء الله نعم .. علاج Anastrozole هو علاج هرموني يُستخدم للسيدات اللواتي انقطعت عنهن الدورة الشهرية، وبصفة عامة هو أكثر كفاءة من التاموكسيفين فإذا كنت من ضمن هذه الفئة العمرية فالعلاج مناسب لك، وإذا لا زالت لديك الدورة الشهرية فأنصح باستخدام إبر gosereline مع هذه الحبوب (Twitter) - Jun 13, 2022
- ||| Nubeqa (darolutamide) / Bayer, Orion Corp
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer (clinicaltrials.gov) - Jun 13, 2022
P2, N=61, Active, not recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Unknown status --> Completed Unknown status --> Active, not recruiting | N=250 --> 61 | Trial completion date: May 2022 --> May 2024 | Trial primary completion date: Dec 2020 --> Dec 2022
- || goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., norethindrone / Generic mfg.
Yes - I do aygestin with Lupron/Zoladex. Are you saying you would do addback, or do longer therapy if they're on addback? (Twitter) - Jun 10, 2022
- |||| goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
Clinical: #Endometriosis Gurus - I'm curious what scenarios prompt you to break the FDA guidelines for #Zoladex #Orlissa #Lupron re longevity of use. I've had mentors who would do a DEXA & keep them on it if the patient was doing well & failed all else. Thoughts? @MigsRunner @Mikhail_MIGS (Twitter) - Jun 10, 2022
- | Firmagon (degarelix) / Astellas, Ferring
Observational data, Journal: Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan. (Pubmed Central) - Jun 8, 2022
Unknown status --> Active, not recruiting | N=250 --> 61 | Trial completion date: May 2022 --> May 2024 | Trial primary completion date: Dec 2020 --> Dec 2022 In patients with PCa and pre-existing CVD, GnRH antagonist use was associated with lower risks for composite CV events and MACE compared with GnRHa.
- | Erleada (apalutamide) / J&J, Airui'en (rezvilutamide) / Jiangsu Hengrui Pharma
New P2 trial, Metastases: Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer (clinicaltrials.gov) - Jun 7, 2022
P2, N=900, Not yet recruiting, Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- ||| goserelin acetate / Generic mfg.
Intersting! I actually had a DIE scan myself with the leading professors here which didn’t find any endometriosis and than was given zoladex and made to get a colonoscopy and told it was IBS after i already had biopsy proven endometriosis… (Twitter) - Jun 3, 2022
- || goserelin acetate / Generic mfg.
God damn it Im a part of that 2%… to think I paid $550 aud for the scan and had a whole surgery to find out it was a false positive. Then I was prescribed zoladex #MakeItMakeSense (Twitter) - Jun 3, 2022
- | goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
Journal: Androgen deprivation therapy for prostate cancer: Prescribing behaviors and preferences among urologists. (Pubmed Central) - May 29, 2022
Overall, one in four urologists were classified as high mono-prescribers. Mono-prescribers had more years in practice and smaller volume practices, potentially suggesting habitual prescription behavior and/or the effect of external pressures.
- | goserelin acetate / Generic mfg.
Trial completion date, Trial primary completion date: SHIP0804: Luteinizing Hormone-Releasing Hormone Agonist Therapy and Iodine I 125 Implant in Treating Patients With Previously Untreated Prostate Cancer (clinicaltrials.gov) - May 25, 2022
P3, N=421, Active, not recruiting, Sponsor: Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Mono-prescribers had more years in practice and smaller volume practices, potentially suggesting habitual prescription behavior and/or the effect of external pressures. Trial completion date: May 2021 --> Mar 2023 | Trial primary completion date: May 2021 --> Apr 2022
- ||| Kisqali (ribociclib) / Novartis
Trial completion date, Combination therapy, Metastases: MONALEESA-7: Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer (clinicaltrials.gov) - May 24, 2022
P3, N=672, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: May 2021 --> Mar 2023 | Trial primary completion date: May 2021 --> Apr 2022 Trial completion date: Jun 2022 --> Sep 2022
- |||| goserelin acetate / Generic mfg., bicalutamide / Generic mfg.
Trial completion date, Trial primary completion date: PCS III: Study on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy Alone (clinicaltrials.gov) - May 23, 2022
P3, N=600, Active, not recruiting, Sponsor: Abdenour Nabid
Trial completion date: Jun 2022 --> Sep 2022 Trial completion date: Dec 2025 --> Dec 2023 | Trial primary completion date: May 2018 --> Dec 2023
- | goserelin acetate / Generic mfg.
Journal: High-Performance Computational Molecular Docking for Potential Inhibitors of an Essential Enzyme of Burkholderia pseudomallei. (Pubmed Central) - May 14, 2022
Significantly departing from this range, goserelin acetate scored the highest overall, with a GOLD score of 101.9...Promising ligands will be obtained and then evaluated through binding and enzymatic assays to verify their ability to inhibit the enzyme. If confirmed, these novel ligands may be potential candidates for further drug development to treat melioidosis.
- || giredestrant (GDC-9545) / Roche
Trial completion date, Trial primary completion date, Combination therapy, Metastases: GO39932: A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer (clinicaltrials.gov) - May 13, 2022
P1a/1b, N=181, Active, not recruiting, Sponsor: Genentech, Inc.
If confirmed, these novel ligands may be potential candidates for further drug development to treat melioidosis. Trial completion date: Sep 2022 --> Mar 2023 | Trial primary completion date: Sep 2022 --> Mar 2023
- | Firmagon (degarelix) / Astellas, Ferring, Orgovyx (relugolix) / Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Dainippon
Journal: THE CARDIOVASCULAR EFFECTS OF GNRH ANTAGONISTS IN MEN WITH PROSTATE CANCER. (Pubmed Central) - May 11, 2022
Trial completion date: Sep 2022 --> Mar 2023 | Trial primary completion date: Sep 2022 --> Mar 2023 There is consistent but methodologically limited data to suggest that GnRH antagonists-a relatively new class of androgen deprivation therapy for prostate cancer-cause significantly less cardiovascular adverse effects than the more frequently used GnRH agonists.
- ||| Kisqali (ribociclib) / Novartis
Trial completion date, Combination therapy, Metastases: CompLEEment-1: Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC (clinicaltrials.gov) - May 9, 2022
P3, N=3246, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
There is consistent but methodologically limited data to suggest that GnRH antagonists-a relatively new class of androgen deprivation therapy for prostate cancer-cause significantly less cardiovascular adverse effects than the more frequently used GnRH agonists. Trial completion date: Jun 2022 --> Sep 2022
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Enrollment open: SPARKLE: Metastasis-directed Therapy for Oligorecurrent Prostate Cancer (clinicaltrials.gov) - May 8, 2022
P3, N=873, Recruiting, Sponsor: Universitaire Ziekenhuizen Leuven
Trial completion date: Jun 2022 --> Sep 2022 Active, not recruiting --> Recruiting
- | goserelin acetate / Generic mfg., bicalutamide / Generic mfg.
Journal, Circulating Tumor Cells: Presence of CD133-positive circulating tumor cells predicts worse progression-free survival in patients with metastatic castration-sensitive prostate cancer. (Pubmed Central) - May 6, 2022
Active, not recruiting --> Recruiting Baseline CTC+CD133+ was a poor independent prognostic factor for metastatic castration-sensitive prostate cancer patients to progress to castration-resistant prostate cancer after receiving androgen deprivation therapy.
- ||| goserelin acetate / Generic mfg., bicalutamide / Generic mfg., flutamide / Generic mfg.
P3 data, Journal: High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial. (Pubmed Central) - May 4, 2022
P3
Intermediate-risk patients treated with high-dose radiotherapy do not benefit from LTAD. A biological characterisation with the inclusion of genomic testing is needed in the decision-making process.
- || Kisqali (ribociclib) / Novartis
Trial completion date, Combination therapy, Metastases: Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer. (clinicaltrials.gov) - May 3, 2022
P2, N=327, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
A biological characterisation with the inclusion of genomic testing is needed in the decision-making process. Trial completion date: Dec 2023 --> Dec 2024
- ||| Biomarker, Enrollment change: BOUQUET: A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (clinicaltrials.gov) - May 3, 2022
P2, N=400, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Dec 2023 --> Dec 2024 N=200 --> 400
- ||| Kisqali (ribociclib) / Novartis
Enrollment closed, Metastases: RIGHT Choice: Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Apr 28, 2022
P2, N=225, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=200 --> 400 Recruiting --> Active, not recruiting
- Keytruda (pembrolizumab) / Merck (MSD)
BTCRC-HN17-111, A phase 2 trial of ADT (goserelin) in combination with pembrolizumab for patients with advanced salivary gland tumors expressing androgen receptor (AR). () - Apr 28, 2022 - Abstract #ASCO2022ASCO_6127;
P2
The combination of goserelin and pembrolizumab was well-tolerated and show preliminary evidence of efficacy in the first stage of the trial. The second stage of the trial has opened to accrual with a plan to enroll 11 additional patients.
- Verzenio (abemaciclib) / Eli Lilly
A pilot phase II study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma. (Available On Demand; 401) - Apr 28, 2022 - Abstract #ASCO2022ASCO_5466;
P2
These results compare favorably to published outcomes of neoadjuvant chemotherapy in LGSOC. Further studies are planned to explore this new treatment option in a larger study population.
- tamsulosin / Generic mfg., goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
Profiling of clinically relevant subgroups of asymptomatic or mild-symptomatic metastatic castration-resistant prostate cancer (mCRPC) patients using PSA and testosterone levels and deep learning. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_3744;
P3
Model predictions also suggest complex interactions among many clinical features that might be important modulators of key clinical traits and outcome. Further work is required to validate this approach to anticipate the clinical course of asymptomatic or mildly symptomatic mCRPC patients and help to better decide when to start appropriate therapy.
- Erleada (apalutamide) / J&J
Randomized phase II trial of neoadjuvant androgen deprivation therapy plus abiraterone and apalutamide for patients with high-risk localized prostate cancer: Pathologic response and PSMA imaging correlates. (Available On Demand; 268) - Apr 28, 2022 - Abstract #ASCO2022ASCO_3693;
P2
Although pCR or MRD after intense neoadjuvant ADT was infrequent, a significant proportion of pts achieved a favorable pathologic response with RCB ≤ 0.25 cm3. PSMA-PET response is a potential surrogate for pathologic response.
- Ibrance (palbociclib) / Pfizer
Final result for SAFIA trial for neoadjuvant palbociclib in patients with operable luminal breast cancer responding to fulvestrant. (Available On Demand; 367) - Apr 28, 2022 - Abstract #ASCO2022ASCO_3293;
P3
The addition of palbociclib to neoadjuvant F/G did not show any additional benefit in terms of pathologic response, including pCR in neoadjuvant therapy of Luminal HER2-negative BC responding to induction F/G. The use of an upfront 21-gene assay appeared feasible on biopsy specimens, and the identification of tumors with RS<31 allowed to select endocrine sensitive patients, leading ultimately to a 96% clinical benefit with 8–9 months of F/G neoadjuvant therapy.
- Estradiol (E2) levels in premenopausal women with hormone receptor-positive (HR+) breast cancer (BC) on ovarian function suppression (OFS) with gonadotropin-releasing hormone agonists (GnRHa). (Available On Demand; 296) - Apr 28, 2022 - Abstract #ASCO2022ASCO_3222;
This may be an area amenable to intervention to improve outcomes in young women. However, larger studies are needed to elucidate the optimal E2 target on OFS and clinical implications of incomplete E2 suppression on ultrasensitive assays.
- Erleada (apalutamide) / J&J
Yatagarasu: A single-arm, open-label, phase 2 study of apalutamide (APA) plus goserelin (GOS) for patients (pts) with far locally advanced or recurrent/metastatic (fLA/RM) and androgen receptor (AR)-expressing salivary gland carcinoma (SGC). (Available On Demand; 71) - Apr 28, 2022 - Abstract #ASCO2022ASCO_2313;
P2
This is the first prospective trial evaluating CAB with APA for AR-expressing SGC. Although this study did not meet the predefined criteria of efficacy, clinically meaningful activity with well-tolerated safety profile of APA+GOS was shown.
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
New P3 trial: SPARKLE: Metastasis-directed Therapy for Oligorecurrent Prostate Cancer (clinicaltrials.gov) - Apr 28, 2022
P3, N=873, Active, not recruiting, Sponsor: Universitaire Ziekenhuizen Leuven
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial completion date: Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer (clinicaltrials.gov) - Apr 27, 2022
P2, N=19, Active, not recruiting, Sponsor: University of Colorado, Denver
Although this study did not meet the predefined criteria of efficacy, clinically meaningful activity with well-tolerated safety profile of APA+GOS was shown. Trial completion date: Mar 2020 --> Apr 2023
- Must-have Knowledge about GnRH Agonist for Patients with Breast Cancer (RM 5(Art Hall)) - Apr 22, 2022 - Abstract #GBCC2022GBCC_164;
In the light of increased morbidity with aromatase inhibitors and in the context of the reported data of the SOFT/TEXT trials, most patients are optimally treated with tamoxifen and ovarian function suppression (OFS). However, the option of aromatase inhibitors and OFS should be discussed on an individual basis.
- || Ibrance (palbociclib) / Pfizer
Trial completion: Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer (clinicaltrials.gov) - Apr 20, 2022
P2, N=24, Completed, Sponsor: NSABP Foundation Inc
However, the option of aromatase inhibitors and OFS should be discussed on an individual basis. Active, not recruiting --> Completed
- |||| Kisqali (ribociclib) / Novartis
New P4 trial: Roll-over study to allow continued access to ribociclib (EUDRACT) - Apr 19, 2022
P4, N=137, Ongoing, Sponsor: Novartis Pharma AG
- ||| Kisqali (ribociclib) / Novartis
Clinical, P3 data, Journal: Updated Overall Survival of Ribociclib Plus Endocrine Therapy vs Endocrine Therapy Alone in Pre- and Perimenopausal Patients With HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. (Pubmed Central) - Apr 19, 2022
P3
Ribociclib plus ET continued to show significantly longer OS than ET alone in pre-/perimenopausal patients, including patients aged <40 years, with HR+/HER2- ABC with 53.5 months of median follow-up. (ClinicalTrials.gov, NCT02278120).
- | goserelin acetate / Generic mfg., tamoxifen / Generic mfg.
New P2 trial: INTERSTELLAR: OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk (clinicaltrials.gov) - Apr 17, 2022
P2, N=343, Not yet recruiting, Sponsor: Gangnam Severance Hospital
- || goserelin acetate / Generic mfg.
"فارماکوکینتیک گوسرلین داروی Goserelin تقريباً به طور كامل متعاقب تزريق زيرپوستي جذب ميگردد و نيمه عمر حذف سرمي آن 2 تا 4 ساعت ميباشد كه در بيماران مبتلا به اختلالات كليوي اين زمان افزايش مييابد."@merck #cancer (Twitter) - Apr 17, 2022
- || goserelin acetate / Generic mfg.
Clinical: در درمان پروستات يك داروي ضد آندروژن مثل سيپروترون استات را چند روز قبل از شروع درمان با Goserelin تجويز ميكنند و حداقل به صورت 3 هفته ادامه مييابد.@merck #hospitalized (Twitter) - Apr 17, 2022
- ||| Kisqali (ribociclib) / Novartis
P3 data, Clinical Trial,Phase III, Journal: Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial. (Pubmed Central) - Apr 13, 2022
P3
The clinical benefit and overall response rates in males were consistent with the overall population. This analysis demonstrates the safety and efficacy of ribociclib in a close-to-real-world setting, supporting the use of RIB + LET in male patients with HR+, HER2- ABC.
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas, Erleada (apalutamide) / J&J
Trial completion date, Trial primary completion date: Micro RNAs to Predict Response to Androgen Deprivation Therapy (clinicaltrials.gov) - Apr 11, 2022
P=N/A, N=60, Active, not recruiting, Sponsor: Medical College of Wisconsin
This analysis demonstrates the safety and efficacy of ribociclib in a close-to-real-world setting, supporting the use of RIB + LET in male patients with HR+, HER2- ABC. Trial completion date: Jun 2023 --> Jun 2025 | Trial primary completion date: Jun 2022 --> Jun 2024
- Suprefact (buserelin acetate) / Sanofi, Firmagon (degarelix) / Astellas, Ferring
Cardiovascular adverse events-related to GnRH agonists and GnRH antagonists: Analysis of real-life data from Eudra-Vigilance database (Room 225) - Apr 10, 2022 - Abstract #AUA2022AUA_2713;
Real-life data suggest GnRH agonists are associated with higher cardiovascular AEs when compared to GnRH antagonists. Clinicians should consider these data when prescribing HT especially in young patients.
- | goserelin acetate / Generic mfg.
Biomarker, Enrollment open, Trial initiation date, Metastases: Neoadjuvant Hormone and Radiation Therapy Followed by Radical Prostatectomy in Patients With High-Risk Prostate Cancer (clinicaltrials.gov) - Apr 7, 2022
P=N/A, N=38, Recruiting, Sponsor: National Taiwan University Hospital
Clinicians should consider these data when prescribing HT especially in young patients. Not yet recruiting --> Recruiting | Initiation date: Jul 2021 --> Jan 2022
- | Viadur (leuprorelin implant) / J&J, Bayer, Eligard (leuprolide acetate) / Tolmar, Sanofi, Recordati
Trial completion date, Metastases: Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer (clinicaltrials.gov) - Apr 6, 2022
P2, N=29, Active, not recruiting, Sponsor: City of Hope Medical Center
Not yet recruiting --> Recruiting | Initiation date: Jul 2021 --> Jan 2022 Trial completion date: Aug 2021 --> Dec 2022